Analyzing R&D Budgets: Opthea Limited vs Catalyst Pharmaceuticals, Inc.

R&D Investment Trends: Opthea vs Catalyst Pharmaceuticals

__timestampCatalyst Pharmaceuticals, Inc.Opthea Limited
Wednesday, January 1, 2014101177743401685
Thursday, January 1, 2015118013424284228
Friday, January 1, 2016113699413581295
Sunday, January 1, 2017113752374838300
Monday, January 1, 20181991920424891534
Tuesday, January 1, 20191884275231347891
Wednesday, January 1, 20201649671517480747
Friday, January 1, 20211693600034710152
Saturday, January 1, 202219789000108459978
Sunday, January 1, 202393150000181563523
Monday, January 1, 2024176326321
Loading chart...

Unlocking the unknown

A Decade of Innovation: Opthea Limited vs Catalyst Pharmaceuticals, Inc.

In the ever-evolving landscape of pharmaceuticals, research and development (R&D) budgets are a key indicator of a company's commitment to innovation. Over the past decade, Opthea Limited and Catalyst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Opthea Limited's R&D expenses surged by over 5,200%, peaking in 2023 with a remarkable 181 million USD. This reflects their aggressive pursuit of groundbreaking therapies. In contrast, Catalyst Pharmaceuticals, Inc. maintained a more conservative approach, with a steady increase culminating in a 931% rise by 2023. Notably, 2023 marked a significant leap for Catalyst, with R&D expenses reaching 93 million USD, a tenfold increase from 2014. These trends underscore the dynamic nature of pharmaceutical innovation, where strategic R&D investments can shape the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025